Loading…
Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase 3 clinical trials. The company also develops programs focused on various targets, including haploinsufficiency diseases of the central nervous system and eye. It has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome; and Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of genetic neurodevelopmental diseases. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $184M | $-19M | $-7M | $45M | -2.0% | 404.5% | -92.3% |
| 2024 | $37M | $-99M | $-89M | $-87M | -38.9% | 316.3% | -15.0% |
| 2023 | $9M | $-112M | $-105M | $-83M | -65.6% | -29.2% | 3.6% |
| 2022 | $12M | $-103M | $-101M | $-36M | -54.7% | - | - |
| 2021 | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 12.40 | 8.78 | 36.56 | 184.42 |
| Operating Revenue | - | 12.40 | 8.78 | 36.56 | 184.42 |
| Operating Expense | - | 116.76 | 123.55 | 137.93 | 205.01 |
| Research And Development | - | 77.84 | 82.23 | 89.13 | 137.92 |
| Selling General And Administration | - | 38.92 | 41.32 | 48.79 | 67.09 |
| Total Expenses | - | 116.76 | 123.55 | 137.93 | 205.01 |
| Operating Income | - | -104.36 | -114.77 | -101.37 | -20.59 |
| Total Operating Income As Reported | - | -104.36 | -114.77 | -101.37 | -20.59 |
| EBITDA | - | -102.81 | -112.30 | -99.20 | -18.82 |
| Normalized EBITDA | - | -102.81 | -112.30 | -99.20 | -18.82 |
| EBIT | - | -104.36 | -114.77 | -101.37 | -20.59 |
| Interest Income | 0.12 | - | - | - | - |
| Net Interest Income | - | 3.12 | 9.91 | 12.64 | 13.76 |
| Other Non Operating Income Expenses | - | 0.17 | 0.17 | -0.25 | -0.05 |
| Other Income Expense | - | 0.17 | 0.17 | -0.25 | -0.05 |
| Interest Income Non Operating | 0.12 | - | - | - | - |
| Net Non Operating Interest Income Expense | - | 3.12 | 9.91 | 12.64 | 13.76 |
| Pretax Income | - | -101.07 | -104.70 | -88.98 | -6.88 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | -101.07 | -104.70 | -88.98 | -6.88 |
| Net Income From Continuing And Discontinued Operation | - | -101.07 | -104.70 | -88.98 | -6.88 |
| Net Income From Continuing Operation Net Minority Interest | - | -101.07 | -104.70 | -88.98 | -6.88 |
| Net Income | - | -101.07 | -104.70 | -88.98 | -6.88 |
| Net Income Common Stockholders | - | -101.07 | -104.70 | -88.98 | -6.88 |
| Net Income Including Noncontrolling Interests | - | -101.07 | -104.70 | -88.98 | -6.88 |
| Normalized Income | - | -101.07 | -104.70 | -88.98 | -6.88 |
| Diluted NI Availto Com Stockholders | - | -101.07 | -104.70 | -88.98 | -6.88 |
| Basic Average Shares | 36.74 | 38.90 | 43.99 | 54.01 | - |
| Diluted Average Shares | 36.74 | 38.90 | 43.99 | 54.01 | - |
| Reconciled Depreciation | - | 1.55 | 2.47 | 2.18 | 1.77 |
| General And Administrative Expense | - | 38.92 | 41.32 | 48.79 | 67.09 |
| Other Gand A | - | 38.92 | 41.32 | 48.79 | 67.09 |
| Total Other Finance Cost | - | -3.12 | -9.91 | -12.64 | -13.76 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Stoke Therapeutics, Inc.this co. | STOK | $1.9B | -272.47 | 5.32 | -2.0% | -95.36 |
| Ocular Therapeutix, Inc. | OCUL | $1.9B | -7.25 | 2.94 | -40.6% | -5.07 |
| Harmony Biosciences Holdings, Inc. | HRMY | $1.9B | 12.02 | 2.19 | 18.2% | 5.17 |
| Astrana Health, Inc. | ASTH | $1.9B | 83.46 | 2.41 | 2.9% | 18.67 |
| Pulse Biosciences, Inc. | PLSE | $1.9B |
| - |
| - |
| - |
| - |
| - |
| - |
| -25.62 |
| 23.12 |
| -90.2% |
| -23.61 |
| Zymeworks Inc. | ZYME | $1.8B | -22.76 | 6.88 | -30.2% | -22.40 |
| Maravai LifeSciences Holdings, Inc. | MRVI | $1.8B | -14.08 | 8.67 | -61.6% | -13.48 |
| Pediatrix Medical Group, Inc. | MD | $1.8B | 11.11 | 2.12 | 19.1% | 7.64 |
| Viridian Therapeutics, Inc. | VRDN | $1.8B | -5.34 | 3.10 | -58.1% | -4.95 |
| Peer Median | - | -6.29 | 3.02 | -35.4% | -5.01 | |